This trial pursues studying a compassionate treatment option for patients with inoperable pseudomyxoma peritonei through percutaneous administration of bromelain + N-acetylcysteine (NAC) in order to decrease tumoral volume. Secondary endpoints are the decrease of ascites, compressive symptoms and pain through the dilution of mucins, which would better intestinal blockage.

Inclusion Criteria:

• Pseudomyxoma peritonei diagnosis through imaging tests and/or histological studies
• Pseudomyxoma peritonei relapse in abdominal area in patients who comply inoperability criteria, which are:

At least two HIPEC operations or major abdominal surgery (PSS > 3). Patients with acute morbidities (ASA score IV)

• ECOG 0-2
• Age ≥ 18
• Signs informed consent

Exclusion Criteria:

• Candidates to other potentially healing treatments
• Allergy to bromelains (pineapple), N-Acetylcysteine or possible cross-reactive allergy (eggs, sulphate. latex, carrots, celery, wheat...)
• Non-manageable coagulation alterations
• No possibility of intraabdominal drainage catheter
• Acute respiratory pathology (asthma, COPD), acute hepatic, cardiopathic or kidney pathology
• Allergy to any substance that might cause crossed reactivity to bromelain
• Unwillingness to participate in this clinical trial

Data will be shared after the study concludes and results are published

After results publication

Upon request to study's principal investigator